Gary Mishkin has a BA in Economics from Brandeis University, an MS in Medical Engineering from George Washington University, and an MBA from the University of Virginia’s Darden School of Business.
Mr. Mishkin spent seven (7) years performing Clinical Research focused on kidney dialysis in the Division of Renal Diseases and Hypertension at the George Washington University. Mr. Mishkin conducted clinical trials on medical devices and pharmaceutical drugs and performed original research to improve the understanding and delivery of dialysis care. He has presented his research at medical conferences throughout the world.
Mr. Mishkin also worked for Alcavis International, Inc., an infection control company located in Gaithersburg, Maryland, He started his career in industry as VP Research and Development and, over time, moved on to become Chief Operations Officer as the company grew, merged, and was acquired by a large international pharmaceutical company. During this time, Mr. Mishkin maintained his ties to the research community having received several NIH STTR Grants with the Washington, DC VA Medical Center for the development of a new hemodialyzer for kidney dialysis.
Mr. Mishkin founded Apollo Renal Therapeutics, LLC (DBA Artemis Plastics) to produce and commercialize his hemodialyzer. In 2014, Mr. Mishkin acquired the assets of an injection molding contract manufacturing company in Ocala, Florida. His goal is to continue to expand the medical device contract manufacturing business, as he completes the development and testing of the novel hemodialyzer. Apollo Renal Therapeutics, LLC allows him to focus on his passion of medical device research and his love of manufacturing and business.
Mr. Mishkin has also published his research in peer-reviewed journals and has more than a dozen US and International Patents for products he has developed.